



Official reprint from UpToDate®

www.uptodate.com © 2023 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Wolters Kluwer

Society guideline links: Attention deficit hyperactivity disorder

Introduction

This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

International

- [International consensus statement for the screening, diagnosis, and treatment of adolescents with concurrent attention-deficit/hyperactivity disorder and substance use disorder \(2020\)](#)

Canada

- [Canadian ADHD Resource Alliance \(CADDRA\): Canadian ADHD practice guidelines, 4.1 edition \(2020\)](#)
- [Choosing Wisely Canada: Don't administer psychostimulant medications to preschool children with Attention Deficit Disorder \(ADD\), but offer parent-administered behavioural therapy \(2020\)](#)
- [Choosing Wisely Canada: Don't use atypical antipsychotics as a first-line intervention for Attention Deficit Hyperactivity Disorder \(ADHD\) with disruptive behaviour disorders \(2020\)](#)

- [Choosing Wisely Canada: Don't use psychostimulants as a first-line intervention in preschool children with ADHD \(2020\)](#)
 - [Canadian Paediatric Society \(CPS\): Position statement on ADHD in children and youth – Part 1: Etiology, diagnosis, and comorbidity \(2018\)](#)
 - [CPS: Position statement on ADHD in children and youth – Part 2: Treatment \(2018\)](#)
 - [CPS: Position statement on ADHD in children and youth – Part 3: Assessment and treatment with comorbid ASD, ID, or prematurity \(2018\)](#)
 - [CPS: Position statement for screening for disruptive behaviour problems in preschool children in primary health care settings \(2017\)](#)
 - [Autism Speaks Autism Treatment Network Psychopharmacology Committee \(ATN-PC\): Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders \(2012\)](#)
 - [CPS, the Canadian Cardiovascular Society \(CCS\), and the Canadian Academy of Child and Adolescent Psychiatry \(CACAP\): Position statement on cardiac risk assessment before the use of stimulant medications in children and youth \(2009\)](#)
-

United States

- [Centers for Disease Control and Prevention \(CDC\): Attention-deficit/hyperactivity disorder \(ADHD\)](#)
- [American Academy of Pediatrics \(AAP\): Clinical report for the evaluation and management of children and adolescents with acute mental health or behavioral problems – Part I: Common clinical challenges of patients with mental health and/or behavioral emergencies \(2016, reaffirmed 2022\)](#)
- [AAP: Clinical report for the evaluation and management of children with acute mental health or behavioral problems – Part II: Recognition of clinically challenging mental health related conditions presenting with medical or uncertain symptoms \(2016, reaffirmed 2022\)](#)
- [AAP: Clinical report on promoting optimal development – Identifying infants and young children with developmental disorders through developmental surveillance and screening \(2020\)](#)

- [Society for Developmental and Behavioral Pediatrics \(SDBP\): Clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit/hyperactivity disorder \(2020\)](#)
 - [AAP: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents \(2019\)](#)
 - [AAP: Clinical report on school-aged children who are not progressing academically – Considerations for pediatricians \(2019\)](#)
 - [American Academy of Neurology \(AAN\): Practice advisory for the utility of EEG theta/beta power ratio in ADHD diagnosis \(2016\)](#)
 - [Autism Speaks Autism Treatment Network Psychopharmacology Committee \(ATN-PC\): Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders \(2012\)](#)
-

Europe

- [European ADHD Guidelines Group: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents \(2013\)](#)
 - [European Network for Hyperkinetic Disorders \(EUNETHYDIS\): European guidelines on managing adverse effects of medication for ADHD \(2011\)](#)
-

United Kingdom

- [Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus \(2020\)](#)
- [National Institute for Health and Care Excellence \(NICE\): Guideline on attention deficit hyperactivity disorder – Diagnosis and management \(2018, updated 2019\)](#)
- [NICE: Quality standard on attention deficit hyperactivity disorder \(2013, updated 2018\)](#)
- [British Association for Psychopharmacology \(BAP\): Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder, update \(2014\)](#)

India

- [Indian Academy of Pediatrics \(IAP\): Consensus statement on evaluation and management of attention deficit hyperactivity disorder \(2017\)](#)

Use of UpToDate is subject to the [Terms of Use](#).

Topic 117871 Version 16.0

